DOCSLIB.ORG

FACT SHEET Acrylfentanyl

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FACT SHEET Acrylfentanyl FACT SHEET Acrylfentanyl May 2017 For more information, please contact: Dr. P. Blanckaert Coordinator Belgian Early Warning System Drugs Scientific Institute of Public Health National Focal Point on Drugs Jyliette Wytsmanstraat 14 B-1050 Brussels, Belgium Tel : 02/642 5408 [email protected] Science at the service of Public health, Food chain safety and Environment. The information in this message is exclusively meant for the EWS-network, and was sent to you, as a member of this network, in a confidential way. Therefore the information in this message may not be copied, transferred or made public without the prior permission of the WIV-ISP. The WIV-ISP takes responsibility for the editing of a press release, if considered as necessary in the framework of its mission. The information contained in this document is also available on the BEWSD-website (with corresponding pdf-files and analytical data). This part of the website is not accessible for the general public. A login can be requested by contacting [email protected]. © Scientific Institute of Public Health, Brussels 2011 This report may not be reproduced, published or distributed without the consent of the ISP | WIV. A. General information Recent sample in Belgium In the first half of May 2017, a death was reported in Belgium after the use of acrylfentanyl. The victim, male, presumably consumed a powder containing acrylfentanyl by sniffing, and was found dead at the scene, in the region of Ghent. It remains unclear whether the victim knowingly consumed acrylfentanyl. Several other powders and tablets were found at the scene, one of which was identified as N- ethylhexedrone, a cathinone of the stimulant category. Created July 2016 Updated May 2017 Type Narcotic drugs Group Opioids Name Acryloylfentanyl/acrylfentanyl Nature of substance Acryloylfentanyl is a piperidinamine, which is structurally related to internationally controlled opiod fentanyl (Schedule I of the 1961 United Nations Single Convention On Narcotic Drugs). They differ in the double bond present in the 2- position of the propane attached to the N-phenyl moiety. Acryloylfentanyl is also structurally related to acetylfentanyl, which has been recently subjected to international control (Schedule I, 1961 UN Convention). Because of the structural similarity of acryloylfentanyl and fentanyl, their GC-MS may be similar, with a mass difference of M-2 for the base peak (m/z 243 for acryloylfentanyl). Systematic chemical name N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide Other names Chemical names: 1-phenethyl-4-N-acryloylanilinopiperidine Other names: acrylfentanyl, ACF B. Alerts Alerts 23 deaths associated with acrylfentanyl in Sweden – April – August 2016 The EMCDDA has received reports of 23 deaths associated with acryloyl fentanyl. The deaths occurred between April and August 2016 in Sweden. The presence of acryloyl fentanyl was analytically confirmed in all the cases from biological samples taken from the deceased. The decedents were aged 22 to 54 years old (mean 33, median 29); 4 were female, 19 were male. The cause of death is known for 8 cases: acryloyl fentanyl was the cause of death or a contributing factor in all of them; the remaining 15 cases are still under investigation. Acryloyl fentanyl was the only substance consumed in 2 out of 23 deaths. No details are known regarding the source of the substance or the route of administration except for one case where the death occurred after the person consumed acryloyl fentanyl with friends using a nasal spray. In at least 2 cases the deaths were said to have occurred “suddenly”. Reports to EMCDDA Denmark: On 16 May 2017 the Danish FP reported a post-mortem blood and urine sample analysed on 21.01.2017 by the Department of Forensic Medicine, Aarhus University. The concentration of acryloylfentanyl in blood was 0,0072 mg/kg. Estonia: On 17 November 2016 the Estonian FP informed the death cases of 2016: - 1 pure case of acrylfentanyl death; - 2 cases of combination of acrylfentanyl and regular fentanyl deaths. Latvia: On 10 October 2016 the Latvian FP reported a seizure of 0,3699 g beige powder seized on 24/07/2016 by the Police at Riga. Estonia: On 13 September 2016 the Estonian FP reported 6 seizures of powder during Summer 2016 at Tallin. Finland: On 1 September 2016 the Finnish FP reported a seizure of 99 tablets seized on 8.8.2016. The police seized tablets in the Åland island between Sweden and Finland. Sweden: On 31 August 2016 the Swedish FP reported a seizure of 10ml of liquid seized on 19.04.2016 by the Police at Eskilstuna. Sweden: On 22 August 2016 the Swedish FP reported 23 deaths associated with acryloylfentanyl. The substance has been reported as the cause of death in 5 cases. Slovenia: On 1 August 2016 the Slovenian FP reported a sample of 5g light green powder collected on 10.05.2016 by the National Forensic Laboratory. Sample was shipped from China. C. Pictures Tablet seized in Finland Capsule seized in Denmark D. Clinical information Usage This compound has no known uses, and is currently only found as a (legal) fentanyl derivative sold online as a new psychoactive substance. Health risks Acryloylfentanyl is a potent opioid; overdose risks are higher compared to e.g. heroin or morphine. A study by Zhu measured the analgesic activity of derivatives of fentanyl (mouse, intravenous, hot plate test). This study shows that acryloylfentanyl (ED50= 0.082 mg/kg) and fentanyl (ED50=0.062 mg/kg) have high activity as compared to morphine (ED50=13.9 mg/kg). A study by Essawi reports that, at similar doses, acrylfentanyl had longer-lasting antinociceptive effects than fentanyl (mouse, intraperitoneal, hot plate test). Maryanoff et al. measured the inhibitory concentration in vitro (rat brain opioid receptor, naloxone binding) for acryloylfentanyl (IC50= 1.4 nM), fentanyl (IC50= 1.6 nM) and morphine (IC50= 4.2 nM), indicating that acryloylfentanyl has higher affinity to the opioid receptor. Other uses None known. E. Legal status Currently legal in Belgium. Controlled in Austria, Cyprus, Denmark, Estonia, Finland, Ireland, Latvia, Lithuania, Norway, Poland, Sweden, Turkey, United Kingdom, China. F. Chemistry Other chemical names and variants 1-phenethyl-4-N-acryloylanilinopiperidine Chemical Abstracts Service (CAS) registry number 79279-03-1 (HCl) Molecular information Molecular structure: Molecular formula: C22H26N2O Molecular weight: 334.20 g/mol Identification and analytical profile: It has to be noted that the GC-MS EI-spectra of acryloylfentanyl and fentanyl are similar, but with a mass difference of M-2 for the base peak (m/z 243 for acryloylfentanyl). Analytical spectra can be found at the end of this fact sheet, and were provided by the EDND-website of the EMCDDA. These spectra should be considered confidential, and should not be shared without permission. G. Recent references Davide Guerrieri, Emma Rapp, Markus Roman, Gunilla Thelander, Robert Kronstrand, Acrylfentanyl: Another new psychoactive drug with fatal consequences, Forensic Science International http://dx.doi.org/10.1016/j.forsciint.2017.05.010 Ujváry I, et al. Acryloylfentanyl, a recently emerged new psychoactive substance: a comprehensive review. Forensic Tox. 2017. doi: http://dx.doi.org/10.1007/s11419- 017-0367-8 Watanabe S, et al. In vitro and in vivo metabolite identification studies for the new synthetic opioids acetylfentanyl, acrylfentanyl, furanylfentanyl, and 4-fluoro- isobutyrylfentanyl. AAPS J. 2017. doi: https://dx.doi.org/10.1208/s12248-017-0070-z Helander A, et al. Intoxications involving acrylfentanyl and other novel designer fentanyls – results from the Swedish STRIDA project. Clin Tox. 2017. doi: http://dx.doi.org/10.1080/15563650.2017.1303141 J. Suzuki, S. El-Haddad, A review: Fentanyl and non-pharmaceutical fentanyls, Drug and Alcohol Dependence 171 (2017) 107–116, http://dx.doi.org/10.1016/j.drugalcdep.2016.11.033 Anders Helander & Matilda Bäckberg (2016): New Psychoactive Substances (NPS) – the Hydra monster of recreational drugs, Clinical Toxicology. Figure 6: Mass spectrum for precursor (+MS) (top) and product ions (+bbCID) (bottom) for fentanyl, (C22H28N2O). The product ion at m/z 188.1437 corresponds to C13H18N, which is a well known fragmentation pathway for fentanyl. Figure 7: Mass spectrum for precursor (+MS) (top) and product ions (+bbCID) (bottom) for acrylfentanyl, (C22H28N2O). The product ion at m/z 188.1437 corresponds to C13H18N, which is a well known fragmentation pathway for fentanyl. Supporting information for: Identification of a new psychoactive substance in seized material: The synthetic opioid N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]prop-2-enamide (Acrylfentanyl) Table of contents Characterisation of acrylfentanyl (seized sample) 2 1 Acrylfentanyl (seized sample), H NMR, 400 MHz (CD3OD) 2 Acrylfentanyl (seized sample), COSY, 400 MHz(CD3OD) 3 Acrylfentanyl (seized sample), MALDI-TOF HRMS 3 Characterisation of fentanyl (standard) 4 1 Fentanyl (standard), H NMR, 400 MHz (CD3OD) 4 Fentanyl (standard), MALDI-TOF HRMS 5 Acrylfentanyl (seized sample) compared to acrylfentanyl (standard), 1 H NMR, 600 MHz (CDCl3) 5 Enlargements: Acrylfentanyl (seized sample) compared to acrylfentanyl 1 (standard), H NMR, 600 MHz (CDCl3) 6 Acrylfentanyl (seized sample) compared to acrylfentanyl (standard), DEPT, 600 MHz (CDCl3) 7 1 Acrylfentanyl (seized sample), H NMR, 600 MHz (DMSO-d6) 7 Acrylfentanyl (seized sample) compared to triethylamine hydrochloride, DEPT, 600 MHz (DMSO-d6) 8 Acrylfentanyl (seized sample) spiked with triethylamine hydrochloride, 1 H NMR,
Load more

Recommended publications
  • A Review of Synthetic Fentanyl Metabolism and the Metabolism of Select Synthetic Fentanyl Analogues
    A review of synthetic fentanyl metabolism and the metabolism of select synthetic fentanyl analogues Gerard Lee A thesis submitted for the completion of a degree in Master of Forensic Science (Professional Practice) in The School of Veterinary and Life Sciences Murdoch University Supervisors: Associate Professor James Speers (Murdoch) Associate Professor Bob Mead (Murdoch) Semester 1, 2019 i Declaration I declare that this thesis does not contain any material submitted previously for the award of any other degree or diploma at any university or other tertiary institution. Furthermore, to the best of my knowledge, it does not contain any material previously published or written by another individual, except where due reference has been made in the text. Finally, I declare that all reported experimentations performed in this research were carried out by myself, except that any contribution by others, with whom I have worked is explicitly acknowledged. ii Acknowledgements I would like to thank my supervisor Bob Mead for his time guiding me and providing feedback on this endeavour. He has been a great help providing insights and advice from when I started university at Murdoch until now for which I am extremely grateful. To James Speers, thank you for helping me find a direction for this project when I started out. And finally, to my family and friends for their encouragement and support. iii Table of Contents Title page. ...............................................................................................................................I
    [Show full text]
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • Opioid Receptorsreceptors
    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
    [Show full text]
  • Problems of Drug Dependence 1980 Proceedings of the 42Nd Annual Scientific Meeting the Committee on Problems of Drug Dependence
    National Institute on Drug Abuse MONOGRAPH SERIES Problems of Drug Dependence 1980 Proceedings of the 42nd Annual Scientific Meeting The Committee on Problems of Drug Dependence, Inc. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Problems of Drug Dependence, 1980 Proceedings of the 42nd Annual Scientific Meeting, The Committee on Problems of Drug Dependence, Inc. Editor: Louis S. Harris, Ph.D. NIDA Research Monograph 34 February 1981 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse Division of Research 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 The NIDA Research Monograph series is prepared by the Division of Research of the National Institute on Drug Abuse. Its primary objective is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, integrative research reviews and significant original research. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisory Board Avram Goldstein, M.D. Addiction Research Foundation Palo Alto, California Jerome Jaffe, M.D. College of Physicians and Surgeons Columbia University, New York Reese T. Jones, M.D. Langley Porter Neuropsychiatric Institute University of California San Francisco, California William McGlothlin, Ph.D. Deportment of Psychology, UCLA Los Angeles, California Jack Mendelson, M.D. Alcohol and Drug Abuse Research Center Harvard Medical School McLean Hospital Belmont, Massachusetts Helen Nowlis, Ph.D. Office of Drug Education, DHHS Washington, D.C Lee Robins, Ph.D.
    [Show full text]
  • Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
    Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A.
    [Show full text]
  • Understanding and Challenging the Drugs: Chemistry and Toxicology
    UNDERSTANDING AND CHALLENGING THE DRUGS: CHEMISTRY AND TOXICOLOGY Presenter: • Dr. Jasmine Drake, Graduate Program Director and Assistant Professor, Administration of Justice Department, Barbara Jordan-Mickey Leland School of Public Affairs, Texas Southern University NACDL Training Defending Drug Overdose Homicides in Pennsylvania Penn State Harrisburg, Middletown, PA November 6th, 2019 11:30- 12:45 p.m. Understanding & Challenging the Drugs: Chemistry & Toxicology Dr. Jasmine Drake, Forensic Science Learning Laboratory, Texas Southern University I. Opioid Drug Classifications A. Types of Opioids B. Classic vs. Synthetic C. Toxicology of Opioids 1) How opioids interact with the body 2) Addiction (psychological vs. physiological II. New Classes of Drugs A. Emerging Threats B. Potency III. National Trends in Opioid Overdose Deaths in the U.S. A. Based on State B. Ethnicity C. Drug-Type (prescription vs. fentanyl vs. heroin) IV. Trends of Opioid Overdose Deaths in Philadelphia A. Based on Ethnicity B. Drug Type (prescription vs. fentanyl vs. heroin) V. Legal Considerations to the Opioid Epidemic A. Punitive Measures vs. Rehabilitative Treatment B. Progressive Jurisdictions Nationwide C. New Legal Measures in Philadelphia VI. Toxicology Reports A. What’s in the report? B. Key Aspects of the Tox Report C. Terminology D. Evaluating and Interpreting the data? E. Questions and considerations. VII. Conclusion and Discussion A. Case Specific Examples B. Sample Toxicology Reports The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Comparison Between Morphine and Morphine Plus Ketamine for Postoperative Pain Relief After Orthopaedic Surgery
    Ο University of Khartoum Faculty of Medicine Postgraduate Medical Studies Board Comparison between Morphine and Morphine plus Ketamine for postoperative pain relief after orthopaedic surgery By Dr. Sarah Mahmoud Nuri M.B.B.S, (University of Khartoum) A thesis submitted in partial fulfilment for the requirements of the degree of Clinical MD in anaesthesia & intensive care, May 2004 Supervisor Prof. Ali Ahmed Salama MBBS, DA, FFA Faculty of Medicine Neelain University To my mother ...... My grateful acknowledgement is made to Dr. Ali Ahmed Salama for his supervision, encouragement, and advice during the performance of this study. I'm also grateful to all orthopaedic registrars and house officers who helped me in collecting the data. I’m also grateful to Dr. Yassir Salih for his great help and support. I would like also to thank my family for their help and support. LIST OF ABBREVIATIONS CAMP Cyclic adenosine mono phosphate. PIP2 Phosphatidyl inositol di phosphate. IP3 Inositol tri phosphate. ADH Anti Diuretic Hormone. GF Glumerular Filtration. BP Blood Pressure. ECG Electro cadiogram. CBF Cerebral Blood Flow GI Gastro Intestinal CNS Central Nervous system ASA American Society of Anesthiologist VAS Visual analogue scale. NSAIDs Non steroidal anti infalammatory drugs. NMDA N-methyl- D- Aspartate GFR Glumerular filtration rate. EEG Electroencephalogram. ABSTRACT The aim of this study is detection of the efficacy of ketamine in low doses as a potent analgesic and it's ability to provide superior analgesia when added to morphine. It compared morphine with ketamine to morphine alone in Quasi experimental design of post surgical pain control . Also this study compared the incidence of morphine common side effects between the two groups.
    [Show full text]
  • Comprehensive Multi-Analytical Screening Of
    COMPREHENSIVE MULTI-ANALYTICAL SCREENING OF DRUGS OF ABUSE, INCLUDING NEW PSYCHOACTIVE SUBSTANCES, IN URINE WITH BIOCHIP ARRAYS APPLIED TO THE EVIDENCE ANALYSER Darragh J., Keery L., Keenan R., Stevenson C., Norney G., Benchikh M.E., Rodríguez M.L., McConnell R. I., FitzGerald S.P. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: [email protected] Introduction Biochip array technology allows the simultaneous detection of multiple drugs from a single undivided sample, which This study summarises the analytical performance of three different biochip arrays applied to the screening of increases the screening capacity and the result output per sample. Polydrug consumption can be detected and by acetylfentanyl, AH-7921, amphetamine, barbiturates, benzodiazepines (including etizolam and clonazepam), incorporating new immunoassays on the biochip surface, this technology has the capacity to adapt to the new trends benzoylecgonine/cocaine, benzylpiperazines, buprenorphine, cannabinoids, carfentanil, dextromethorphan, fentanyl, in the drug market. furanylfentanyl, meprobamate, mescaline, methamphetamine, methadone, mitragynine, MT-45, naloxone, ocfentanyl, opioids, opiates, oxycodone, phencyclidine, phenylpiperazines, salvinorin, sufentanil, synthetic cannabinoids (JWH-018, UR-144, AB-PINACA, AB-CHMINACA), synthetic cathinones [mephedrone, methcathinone, alpha- pyrrolidinopentiophenone (alpha-PVP)], tramadol, tricyclic antidepressants, U-47700, W-19, zolpidem. Methodology Three different biochip arrays were used (DOA ULTRA,
    [Show full text]
  • Critical Review Report: CROTONYLFENTANYL
    Critical Review Report: CROTONYLFENTANYL Expert Committee on Drug Dependence Forty-second Meeting Geneva, 21-25 October 2019 This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization 42nd ECDD (2019): Crotonylfentanyl © World Health Organization 2019 All rights reserved. nd This is an advance copy distributed to the participants of the 42 Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday Et Al
    US 20110245287A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0245287 A1 Holaday et al. (43) Pub. Date: Oct. 6, 2011 (54) HYBRD OPOD COMPOUNDS AND Publication Classification COMPOSITIONS (51) Int. Cl. A6II 3/4748 (2006.01) C07D 489/02 (2006.01) (76) Inventors: John W. Holaday, Bethesda, MD A6IP 25/04 (2006.01) (US); Philip Magistro, Randolph, (52) U.S. Cl. ........................................... 514/282:546/45 NJ (US) (57) ABSTRACT Disclosed are hybrid opioid compounds, mixed opioid salts, (21) Appl. No.: 13/024,298 compositions comprising the hybrid opioid compounds and mixed opioid salts, and methods of use thereof. More particu larly, in one aspect the hybrid opioid compound includes at (22) Filed: Feb. 9, 2011 least two opioid compounds that are covalently bonded to a linker moiety. In another aspect, the hybrid opioid compound relates to mixed opioid salts comprising at least two different Related U.S. Application Data opioid compounds or an opioid compound and a different active agent. Also disclosed are pharmaceutical composi (60) Provisional application No. 61/302,657, filed on Feb. tions, as well as to methods of treating pain in humans using 9, 2010. the hybrid compounds and mixed opioid salts. Patent Application Publication Oct. 6, 2011 Sheet 1 of 3 US 2011/0245287 A1 Oral antinociception of morphine, oxycodone and prodrug combinations in CD1 mice s Tigkg -- Morphine (2.80 mg/kg (1.95 - 4.02, 30' peak time -- (Oxycodone (1.93 mg/kg (1.33 - 2,65)) 30 peak time -- Oxy. Mor (1:1) (4.84 mg/kg (3.60 - 8.50) 60 peak tire --MLN 2-3 peak, effect at a hors 24% with closes at 2.5 art to rigg - D - MLN 2-45 (6.60 mg/kg (5.12 - 8.51)} 60 peak time Figure 1.
    [Show full text]
  • WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/109445 Al 16 August 2012 (16.08.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/485 (2006.01) A61P 25/04 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US20 12/024482 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, ' February 2012 (09.02.2012) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 13/024,298 9 February 201 1 (09.02.201 1) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): QRX- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, PHARMA LTD.
    [Show full text]